Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 November 2021Website:
http://www.2seventybio.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:25:32 GMTDividend
Analysts recommendations
Institutional Ownership
TSVT Latest News
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.
What type of business is 2seventy bio?
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
What sector is 2seventy bio in?
2seventy bio is in the Healthcare sector
What industry is 2seventy bio in?
2seventy bio is in the Biotechnology industry
What country is 2seventy bio from?
2seventy bio is headquartered in United States
When did 2seventy bio go public?
2seventy bio initial public offering (IPO) was on 03 November 2021
What is 2seventy bio website?
https://www.2seventybio.com
Is 2seventy bio in the S&P 500?
No, 2seventy bio is not included in the S&P 500 index
Is 2seventy bio in the NASDAQ 100?
No, 2seventy bio is not included in the NASDAQ 100 index
Is 2seventy bio in the Dow Jones?
No, 2seventy bio is not included in the Dow Jones index
When was 2seventy bio the previous earnings report?
No data
When does 2seventy bio earnings report?
The next expected earnings date for 2seventy bio is 14 November 2024